As shown in Table 5 (model 1 and model 2), consequences (β = −.55) and treatment control (β = .16) were associated with HRQoL as measured by the CRQ-SAS physical domain. When corrected for the confounders of dyspnoea, FEV1%predicted and comorbidity (Table 5, model 3), consequences (β = −.50) and treatment control (β = .20) were associated with the CRQ-SAS’s physical domain. Consequences, treatment control and dyspnea explained 59% of the variation in the CRQ-SAS’s physical domain (R2 = .59). These results indicate that COPD patients with weaker perceived consequences and more perceived effectiveness of the treatment have better HRQoL as measured by the CRQ-SAS’s physical domain
(the mean of the dyspnoea and fatigue domains).